Navigation Links
Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies
Date:6/16/2011

WALTHAM, Mass., June 16, 2011 /PRNewswire-USNewswire/ -- Background: The U.S. House of Representatives yesterday passed an amendment to H.R. 2112, the House agricultural appropriations bill, co-sponsored by Rep. Don Young (R-AK) and Rep. Lynn Woolsey (D-CA) to prohibit funding for U.S. Food and Drug Administration approval of salmon grown from AquaBounty Technologie's AquAdvantage salmon eggs.  The amendment was voted on by fewer than ten of the total 435 House members.

The U.S. FDA has conducted a rigorous 15-year review of thousands of pages of data and has concluded that these fish are exactly the same as any other Atlantic salmon and, therefore, are safe for consumption.  In addition, the fish will be sterile and required to be grown in self-contained inland tanks, so pose no threat to the environment.  Finally, the United Nations reports that the wild caught fisheries are severely stressed, with  major food species potentially extinct by 2050, yet the demand for fish protein is exploding worldwide. America currently imports more than 97% of the Atlantic salmon consumed here, so Young et al are really supporting foreign salmon producers.

Statement:

"This outrageous action is wrong on the facts, wrong on the process and wrong on the policy.  A handful of representatives have chosen to subvert the FDA's rigorous 15-year plus process. It completely ignores the results of a rigorous scientific review. This sort of political gamesmanship undermines the science-based system that protects the nation's health and safety. It is astonishing that Young and a few colleagues would try to game the system in this way."

"Whether or not you support this transgenic salmon, we should all agree these types of shenanigans have no place in a complex scientific debate.  These actions threaten the fundamental basis of a science-based regulatory process. Americans deserve better from their elected representatives."


'/>"/>
SOURCE AquaBounty Technologies
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Resverlogix Issues a Management Statement
2. Extraordinary General Meetings Statement - XTL Notifies NASDAQ of Compliance with Marketplace Rule 4350(d)(2)
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Sinovac Releases Statement on Healive Vaccine Suspension
5. CV Therapeutics Statement on Unsolicited Proposal From Astellas
6. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
7. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
8. Extraordinary General Meetings Statement -- XTL Also Announces Board and Management Changes
9. Advanced Life Sciences Announces Filing of Shelf Registration Statement
10. Amylin Issues Statement in Response to Carl Icahn
11. DuPont Statement on Obama Administration Biofuels Interagency Working Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Feb. 11, 2016  Bioethics International, a not-for-profit organization focused ... developed, marketed and made accessible to patients around the world, ... had named the publication of the Good Pharma Scorecard ... is also featured as one of BMJ Open ,s ... year that are most frequently read. Ed Sucksmith ...
(Date:2/11/2016)... 11, 2016 --> ... "Company") (OTCQB: PSID), a life sciences company focused ... Thermomedics subsidiary, which markets the Caregiver® FDA-cleared non-contact ... in January 2016, including entering into agreements with ... sales growth, and establishing several near-term pipeline opportunities. ...
(Date:2/10/2016)... - BioAmber Inc. (NYSE: BIOA ), a leader ... & Co. Ltd., its partner in the ... an additional CDN$25 million in the joint venture for ... to 40%.  Mitsui will also play a stronger role ... Sarnia , providing dedicated resources alongside BioAmber,s ...
(Date:2/10/2016)... York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has ... develop new vaccines and immunotherapies for infectious diseases and cancer. , ...
Breaking Biology Technology:
(Date:1/28/2016)... -- Synaptics (NASDAQ: SYNA ), a leading developer of human ... December 31, 2015. --> --> ... 2 percent compared to the comparable quarter last year to $470.5 ... $35.0 million, or $0.93 per diluted share. ... quarter of fiscal 2016 grew 9 percent over the prior year ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/18/2016)... , Jan. 18, 2016  Extenua Inc., ... that simplifies the use and access of ubiquitous ... go-to-market partnership with American Cyber.  ... extensive experience leading transformational C4ISR and Cyber initiatives ... integrating the latest proven technology solutions," said ...
Breaking Biology News(10 mins):